Dr. Lisa Bodei, MD, PHD
Nuclear Medicine (Nuclear Imaging & Therapy Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 707
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Imaging & Therapy Physician primary
NY license 283265
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Nuclear Medicine Group (38 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 707
- Services billed
- 793
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Nuclear medicine study from skull base to mid-thigh with ct scan | 556 | 544 |
| Nuclear medicine study whole body with ct scan | 62 | 61 |
| Radioactive drug therapy through a vein | 38 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
| Nuclear medicine study of bone and/or joint whole body | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $273,673 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.